Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Dopamine Hydrochloride | Dopamine | "4.4 Special warnings and precautions for use, 4.8 Undesirable effect" | Tissue Ischemia,Cardiac Arrhythmias, Hypotension after Abrupt Discontinuation | Apr, 2025 |
| Paclitaxel | Abraxane | 4.6 Fertility, pregnancy and lactation | Use effective contraception for female and male patients with female partners of reproductive potential | Apr, 2025 |
| Desogestrel | Cerazette | 4.5 Interaction with other medicinal products and other forms of interaction | Hormonal contraceptives may interfere with the metabolism of other drugs. Accordingly, plasma and tissue concentrations of other active substances may either increase (e.g. ciclosporin) or decrease. | Apr, 2025 |
| Omeprazole | Aciloc | 4.5 Interaction with other medicinal products and other forms of interaction | Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease omeprazole concentrations. | Mar, 2025 |
| M.M.R II | M.M.R II | 4.5 Interaction with other medicinal products and other forms of interaction | Concomitant administration with other vaccines | Mar, 2025 |
| Abrocitinib | Cibinqo | 6.6 Special precautions for disposal | Keep out of reach and sight of children. | Mar, 2025 |